IS4466A - Samsetning og meðhöndlun fyrir heila- og mænusigg - Google Patents

Samsetning og meðhöndlun fyrir heila- og mænusigg

Info

Publication number
IS4466A
IS4466A IS4466A IS4466A IS4466A IS 4466 A IS4466 A IS 4466A IS 4466 A IS4466 A IS 4466A IS 4466 A IS4466 A IS 4466A IS 4466 A IS4466 A IS 4466A
Authority
IS
Iceland
Prior art keywords
treatment
composition
multiple sclerosis
sclerosis
Prior art date
Application number
IS4466A
Other languages
English (en)
Icelandic (is)
Inventor
Smilek Dawn
Samson Michael
Gefter Malcolm
Hsu Di-Hwei
Shi Jia-Dong
Paliard Xavier
Devaux Brigitte
Rothbard Jonathan
Franzén Henry
Original Assignee
Immulogic Pharmaceutical Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharmaceutical Corporation filed Critical Immulogic Pharmaceutical Corporation
Publication of IS4466A publication Critical patent/IS4466A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS4466A 1994-10-25 1997-04-17 Samsetning og meðhöndlun fyrir heila- og mænusigg IS4466A (is)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32822494A 1994-10-25 1994-10-25
US40422895A 1995-03-15 1995-03-15
PCT/US1995/013682 WO1996012737A2 (en) 1994-10-25 1995-10-25 Compositions and treatment for multiple sclerosis

Publications (1)

Publication Number Publication Date
IS4466A true IS4466A (is) 1997-04-17

Family

ID=26986277

Family Applications (1)

Application Number Title Priority Date Filing Date
IS4466A IS4466A (is) 1994-10-25 1997-04-17 Samsetning og meðhöndlun fyrir heila- og mænusigg

Country Status (15)

Country Link
EP (1) EP0787147A1 (xx)
JP (1) JPH10504039A (xx)
AU (1) AU4278296A (xx)
BR (1) BR9509438A (xx)
CA (1) CA2203629A1 (xx)
CZ (1) CZ122697A3 (xx)
FI (1) FI971750A (xx)
HU (1) HUT77047A (xx)
IL (1) IL115766A0 (xx)
IS (1) IS4466A (xx)
NO (1) NO971900L (xx)
PL (1) PL324091A1 (xx)
SI (1) SI9520118A (xx)
SK (1) SK51297A3 (xx)
WO (1) WO1996012737A2 (xx)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6252040B1 (en) * 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
CA2247009C (en) 1996-03-21 2009-08-04 Imperial College Of Science, Technology And Medicine Cryptic peptides and method for their identification
EP0939826A2 (en) * 1996-08-15 1999-09-08 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
CA2494338C (en) * 1997-04-04 2007-07-17 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
SE9703287D0 (sv) * 1997-09-11 1997-09-11 Astra Ab Peptides
CN1308671A (zh) * 1998-05-05 2001-08-15 科里克萨公司 髓磷脂碱性蛋白肽及其应用
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
WO1999060021A2 (en) * 1998-05-19 1999-11-25 Yeda Research And Development Co. Ltd. Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
EP1288226A1 (en) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modification of the expression levels of Toll-like receptor familiy members for influencing neurodegeneration and neuroprotection in the human central nervous system
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
DE60327618D1 (de) 2002-03-27 2009-06-25 Aegera Therapeutics Inc Gegen iap gerichtete antisense-nukleobasen und deren verwendungen
DE10230381A1 (de) 2002-07-05 2004-01-22 Institut für Medizintechnologie Magdeburg GmbH, IMTM Verwendung von Inhibitoren der Alanyl-Aminopeptidasen und diese umfassende pharmazeutischen Zubereitungen
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
WO2008130382A2 (en) 2006-10-31 2008-10-30 East Carolina University Fusion proteins comprising an anti -inflammatory cytokine and an antigen for treatment of immune disorders
US8815794B2 (en) * 2008-08-28 2014-08-26 The Research Foundation For The State University Of New York Treatment of amyloidoses using myelin basic protein and fragments thereof
EP3348275A3 (en) * 2009-03-31 2018-10-24 East Carolina University Cytokines and neuroantigens for treatment of immune disorders
EA024832B1 (ru) 2009-10-12 2016-10-31 ЛАЙФБИО ЛАБОРАТОРИС ЭлЭлСи Олигопептид, связывающий гидролизующие аутоантитела к основному белку миелина mbp, композиции и способ лечения рассеянного склероза
RU2448685C2 (ru) * 2009-11-30 2012-04-27 Российская Федерация в лице Министерства промышленности и торговли Российской Федерации Липосомы, содержащие олигопептиды - фрагменты основного белка миелина, фармацевтическая композиция и способ лечения рассеянного склероза
CA2830772C (en) 2011-03-21 2020-04-28 Atlantic Cancer Research Institute Polypeptides with affinity for heat shock proteins (hsps) and hsp associated complexes (hacs) and their use in diagnosis and therapy
EP3094341B1 (en) 2014-01-13 2019-10-02 Berg LLC Enolase 1 (eno1) compositions and uses thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (ja) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
US5260422A (en) * 1988-06-23 1993-11-09 Anergen, Inc. MHC conjugates useful in ameliorating autoimmunity
DK0506785T3 (da) * 1989-12-20 2000-07-24 Autoimmune Inc Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener
EP0782859A1 (en) * 1990-03-02 1997-07-09 Autoimmune, Inc. Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens
IL165071A (en) * 1990-03-30 2008-06-05 Autoimmune Inc A peptide with the ability to stimulate a subset of T cells from multiple sclerosis patients
CA2053799C (en) * 1991-10-22 2002-03-12 Kenneth G. Warren Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid
EP0661996A4 (en) * 1991-11-19 1997-05-21 Anergen Inc MHC SUB-UNIT CONJUGATES FOR IMPROVING HARMFUL IMMUNE RESPONSES.
BR9306042A (pt) * 1992-02-28 1997-11-18 Autoimmune Inc Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
IL105153A (en) * 1992-03-25 1999-12-22 Immulogic Pharma Corp Therapeutic compositions comprising peptides derived from human t cell reactive feline protein
DE69320967T2 (de) * 1992-04-09 1999-05-12 Autoimmune Inc Unterdrückung der t-zell proliferation mittels peptidfragmenten des myelin basischen protein
WO1993025661A1 (en) * 1992-06-10 1993-12-23 President And Fellows Of Harvard College Heterogeneous proteolipid peptide 139-151-specific t cell clones
WO1994004121A1 (en) * 1992-08-17 1994-03-03 Autoimmune, Inc. Bystander suppression of retroviral-associated neurological disease
NZ273813A (en) * 1993-09-03 1998-05-27 Immulogic Pharma Corp Myelin oligodendrocyte glycoprotein autoantigen
WO1995007096A1 (en) * 1993-09-06 1995-03-16 La Trobe University Treatment of autoimmune disease
CA2172512A1 (en) * 1993-09-22 1995-03-30 Lawrence Steinman Interaction of t-cell receptors and antigen in autoimmune disease
AU686797B2 (en) * 1994-04-08 1998-02-12 Brigham And Women's Hospital Treatment of autoimmune disease using oral tolerization and/or type I interferon
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
JPH10500109A (ja) * 1994-05-10 1998-01-06 イミユロジク・フアーマシユーチカル・コーポレーシヨン 多発性硬化症のための組成物および治療方法
JP3558347B2 (ja) * 1994-06-09 2004-08-25 ネーデルランセ オルハニサチエ フォール トゥーヘパスト−ナツールウェーテンシャッペルック オンデルズク テーエヌオー 自己免疫疾患、とくに多発性硬化症の診断および治療における使用のためのアルファｂクリスタリン
US6329499B1 (en) * 1994-11-18 2001-12-11 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues of human myelin basic protein
CA2205532A1 (en) * 1994-11-18 1996-05-30 Neurocrine Biosciences, Inc. Methods for treatment of multiple sclerosis using peptide analogues at position 91 of human myelin basic protein

Also Published As

Publication number Publication date
HUT77047A (hu) 1998-03-02
NO971900D0 (no) 1997-04-24
BR9509438A (pt) 1997-12-23
SK51297A3 (en) 1998-03-04
FI971750A0 (fi) 1997-04-24
NO971900L (no) 1997-06-25
CZ122697A3 (en) 1997-09-17
JPH10504039A (ja) 1998-04-14
WO1996012737A3 (en) 1996-10-10
AU4278296A (en) 1996-05-15
WO1996012737A2 (en) 1996-05-02
FI971750A (fi) 1997-06-24
IL115766A0 (en) 1996-01-19
PL324091A1 (en) 1998-05-11
EP0787147A1 (en) 1997-08-06
SI9520118A (sl) 1998-08-31
CA2203629A1 (en) 1996-05-02

Similar Documents

Publication Publication Date Title
IS4466A (is) Samsetning og meðhöndlun fyrir heila- og mænusigg
IS4481A (is) Díhýdrópyramídín og notkun þeirra
DE69607321T2 (de) Reinigungsverfahren und zusammensetzung
NO20035726D0 (no) Benzopyran-inneholdende forbindelser og fremgangsmåte for anvendelse derav
DE69526966D1 (de) Hautkräftigende kometische zusammensetzung
DE69513916D1 (de) Oberflächenbehandlungszusammensetzung
DK0804078T3 (da) Sammensætning og anvendelse deraf
NO943763D0 (no) 4-arylamino-benzopyraner og beslektede forbindelser
BR9506832A (pt) N-pirazolilanilinas e n-pirazolilaminopiridinas
FI954773A (fi) Antihypertriglyserideeminen koostumus
DE69620642D1 (de) Reiningungsverfahren und-zusammensetzung
KR960705557A (ko) 항미생물 방법 및 화장품 조성물(antimicrobial method and cosmetic composition)
BR9509688A (pt) Composto e composição farmacêutica
DE69622461T2 (de) Oberflächenbehandlungszusammensetzung
IL113661A0 (en) Compositions and treatment for multiple sclerosis
DE69519913T2 (de) Dauerwellenzusammensetzung
ITMI940362A0 (it) Composizione antitosse
GB9415901D0 (en) Novel compounds and treatment
NO972216D0 (no) Acrotein-frigjörende sammensetning og dens anvendelse
GB9415900D0 (en) Novel compounds and treatment
BR9507133A (pt) N-aril e n-alquilsulfonilaminais
NO952766L (no) Opplösningsmiddelsammensetninger og metoder
BR9505130A (pt) Composto e composiçao farmacêutica
KR950026706U (ko) 치료용 발열기
ZA959033B (en) Composition and treatment for multiple sclerosis